Yanaba Koichi, Asano Yoshihide, Akamata Kaname, Noda Shinji, Aozasa Naohiko, Taniguchi Takashi, Takahashi Takehiro, Toyama Tetsuo, Ichimura Yohei, Sumida Hayakazu, Kuwano Yoshihiro, Miyazaki Miki, Sato Shinichi
Department of Dermatology, Faculty of Medicine, University of Tokyo, Tokyo, Japan.
Int J Rheum Dis. 2016 Jun;19(6):622-7. doi: 10.1111/1756-185X.12288. Epub 2014 Feb 11.
To determine serum galectin-1 levels and their clinical associations in patients with systemic sclerosis (SSc).
Serum galectin-1 levels were examined by enzyme-linked immunosorbent assay in 66 patients with SSc and 24 healthy individuals.
No significant differences were observed in serum galectin-1 levels between patients with SSc (9.4 ± 5.6 ng/mL), and healthy individuals (8.9 ± 1.3 ng/mL). Among patients with SSc, no significant differences were seen in serum galectin-1 levels between those with diffuse cutaneous SSc (8.8 ± 5.7 ng/mL; n = 31) and those with limited cutaneous SSc (10.0 ± 5.4 ng/mL; n = 35). Patients with SSc who had increased galectin-1 levels less often had pitting scars/digital ulcers than those with normal galectin-1 levels (17% vs. 49%; P < 0.01). Consistently, galectin-1 levels were significantly lower in SSc patients with pitting scars/digital ulcers than in those without pitting scars/digital ulcers (6.9 ± 4.8 vs. 10.9 ± 5.5 ng/mL; P < 0.01).
These results suggest that galectin-1 is a protective factor against the development of digital vasculopathy in SSc. In addition, measurement of serum galectin-1 levels may be useful for risk stratification for the development of digital vasculopathy in the early phase of SSc.
测定系统性硬化症（SSc）患者血清半乳糖凝集素-1水平及其临床相关性。
采用酶联免疫吸附测定法检测66例SSc患者和24名健康个体的血清半乳糖凝集素-1水平。
SSc患者（9.4±5.6 ng/mL）与健康个体（8.9±1.3 ng/mL）的血清半乳糖凝集素-1水平无显著差异。在SSc患者中，弥漫性皮肤型SSc患者（8.8±5.7 ng/mL；n = 31）与局限性皮肤型SSc患者（10.0±5.4 ng/mL；n = 35）的血清半乳糖凝集素-1水平无显著差异。与半乳糖凝集素-1水平正常的SSc患者相比，半乳糖凝集素-1水平升高的SSc患者出现点状瘢痕/指端溃疡的情况较少（17% 对49%；P < 0.01）。同样，有 点状瘢痕/指端溃疡的SSc患者的半乳糖凝集素-1水平显著低于无点状瘢痕/指端溃疡的患者（6.9±4.8对10.9±5.5 ng/mL；P < 0.01）。
这些结果表明，半乳糖凝集素-1是SSc患者指端血管病变发展的保护因素。此外，测定血清半乳糖凝集素-1水平可能有助于SSc早期指端血管病变发展的风险分层。
